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Abstract
Non-adherence to multipharmacological treatment increases the risk of morbidity, mortality and hospitalization. We know
little about the perspective of patients with chronic kidney disease regarding factors influencing medicine taking. This
study aimed to synthesize findings from qualitative studies of patients’ experiences of factors that facilitate and hinder
adherence to medication. A systematic review of qualitative studies adhering to the Enhancing transparency in reporting
the synthesis of qualitative research (ENTREQ) framework. Systematic searches were conducted in several databases. We
used thematic synthesis and the Confidence in the Evidence from Reviews of Qualitative Research (CERQual) approach to
assess the confidence of the evidence. Nineteen studies involving 381 patients with chronic kidney disease were included.
We identified three analytical themes; logistics, benchmarking the need for medication; and the quality of the patient-
physician relationship, with seven descriptive sub-themes as factors influencing patients’ adherence to medications.
Helping patients to map their everyday activities and motivating them to associate medications with everyday activities
may facilitate adherence to medications. Addressing patient beliefs about medications, supporting patients in coping with
side effects of medications and eliciting patients’ wishes for involvement in treatment decisions may also facilitate
adherence. Barriers to adherence were the costs of buying medications, and lacking understanding of the indications and
effects of medications. The findings in this synthesis resonate with previous research and extend the known literature by
synthesizing and formally assessing confidence in the evidence.
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Introduction
Adherence to medication is defined as ‘the extent to which the
patient’s behaviour matches agreed recommendations from the
prescriber’ [1]. In chronic kidney disease (CKD), adherence to
medication is a key component of effective disease management
[2, 3]. The main goals of medication are to slow progression of the
disease and monitor and correct disease-associated complica-
tions and comorbidities while treating the underlying aetiology
[3]. Patients with CKD are prescribed a regime of multi-
pharmacological treatment often starting with antihypertensives
and antidiabetics and subsequently phosphate binders, vitamin
D preparations, calcimimetics, erythropoiesis stimulating agents
and iron supplements [4]. This infers a high burden of pill intake
with sometimes >20 pills/day [2]. Managing multiple medications
and health care appointments, including, for some, dialysis sev-
eral times a week, is a challenging task. Not surprisingly, patients
may miss medications, intentionally or un-intentionally (1).
Estimates of non-adherence to medication vary from 17 to 74%
among patients with CKD and from 3 to 80% among patients on
haemodialysis, depending on the methods used to assess non-
adherence [2, 3, 5]. This poses a major obstacle to achieving treat-
ment goals and increases the risk of morbidity, mortality and
hospitalization [3, 4]. Optimizing adherence to medicine is there-
fore a priority issue for health care providers.
There is a growing body of research into non-adherence to
medication among patients with CKD. Quantitative studies
have focused on the incidence of adherence and identification
of potential risk factors for non-adherence [2]. These studies
provide valuable insight into the prevalence of non-adherence
and associated risk factors [2]. They do not, however, uncover
life circumstances that may influence adherence from the
patient perspective. Qualitative research may contribute to our
knowledge by elaborating the patients’ perspectives on non-
adherence. The aim of this qualitative systematic review was to
synthesize the available qualitative research on factors that
facilitate and hinder adherence to medication from the perspec-
tive of patients with CKD.
Materials and methods
A systematic review and thematic synthesis of qualitative stud-
ies was undertaken. The review was prospectively registered in
PROSPERO (CRD42016033070) and conducted according to the
Enhancing Transparency in Reporting the Synthesis of
Qualitative Research (ENTREQ) framework [6].
Inclusion criteria
We considered English-language studies that explored the
experience of medicine taking in adults with CKD. We excluded
studies involving kidney transplant recipients and alternative
medicine. Due to the anticipated limited evidence base, no
search restrictions with regard to year limits were imposed.
Data source and search
We searched MEDLINE, Embase and CINAHL using the system-
atic search method SPIDER (sample, phenomenon of interest,
design, evaluation, research type) [7]. We combined search
terms such as ‘chronic kidney failure’, ‘medication adherence’,
‘qualitative research’, ‘patient experience’ and ‘qualitative
research’ among others (for a full overview of search terms see
Table 1). The search strategy was refined in collaboration with
an experienced librarian and adapted to each database, first
searching each set of search terms using the Boolean operator
OR and subsequently combining these searches using the
Boolean operator AND. Along with the electronic searches, we
manually searched reference lists and grey literature.
We uploaded the search into the Covidence software, where
two authors (T.M.N., T.T.) independently screened the search
results for eligibility. The search was conducted in January 2016
and updated in June 2017. Figure 1 illustrates the literature
search and selection.
Quality assessment
We used the Critical Appraisal Skills Programme (CASP) check-
list for qualitative studies to assess individual study quality [8].
Two authors (T.M.N., M.F.J) independently assessed the studies.
Data extraction and analysis
Included studies were imported into QSR NVivo 10 computer
data analysis software (QRS International, Melbourne, VIC,
Australia). Following the method for thematic synthesis
described by Thomas and Harden [9], we extracted data about
medicine taking from the included studies, for example, all rele-
vant data presented in the ‘abstract, results and discussion’ sec-
tion. To enhance transparency and reproducibility, two authors
(T.M.N., M.F.J.) independently conducted the open line-by-line
coding of extracted data. This resulted in a total of 31 initial
codes that were condensed into 16 preliminary descriptive
themes. The descriptive themes were subsequently discussed in
the author group and a summary of the findings across studies
was drafted. All authors commented on this draft and, through
further discussion of the preliminary descriptive themes, three
analytical themes with seven descriptive sub-themes emerged.
Assessment of confidence in the review findings
We used the Confidence in the Evidence from Reviews of
Qualitative Research (CERQual) criteria to assess how much con-
fidence could be placed in our findings [10, 11]. CERQual is based
on four key components: methodological limitations, relevance
to the review question, coherence and adequacy of the data con-
tributing to a review finding [14]. Methodological limitations of
the individual studies contributing to each review finding were
assessed using the CASP tool. Relevance was assessed by evalu-
ating the applicability of the review findings to the context (per-
spective, population, setting) of our review question. Coherence
was assessed by the extent to which the pattern that constitutes
a review finding was based on evidence that was consistent
across multiple individual studies. Adequacy was assessed
through an overall determination of the degree of richness and
the quantity of data supporting a review finding [11]. After
assessing each of the four components, we judged the confi-
dence in the themes as high, moderate, low or very low. Our
starting point was ‘high confidence’, reflecting the assumption
that each review finding was a reasonable representation of the
phenomenon of interest unless there were CERQual components
that weakened this assumption [11]. See the summary of the
qualitative findings and CERQual assessments in Table 2.
Results
Study characteristics
Of 1044 potentially relevant articles identified in the search, we
included 19 studies [12–30]. In total, 381 patients with CKD
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Table 1. Search method (SPIDER) and search terms used
Search Query
MEDLINE
Sample Search kidney diseases [Mesh] OR kidney failure, chronic [Mesh] OR renal insufficiency [Mesh] OR renal insufficiency,
chronic [Mesh] OR acute kidney injury [Mesh] OR hypertension CKD OR CKD hypertension OR CKD treatment OR haemo-
dialysis OR CKD OR peritoneal dialysis OR renal dialysis/pharmacology [Mesh] or kidney failure, chronic* OR renal dialy-
sis* OR kidney failure, chronic/drug therapy [Mesh] OR kidney failure, chronic/nursing [Mesh] OR kidney disease*
and
Phenomenon
of interest
Search patient compliance/drug effects [Mesh] OR treatment refusal [Mesh] OR self-medication [Mesh] OR self-administra-
tion [Mesh] OR patient medication knowledge [Mesh] OR attitude to health/drug effects [Mesh] OR medication adherence
[Mesh] OR concordance medication OR patient acceptance of health care/drug effects [Mesh] OR drug therapy OR poly-
pharmacy OR treatment refusal* OR medication adherence* OR prescription drug* OR drug*
and
Design Search grounded theory OR hermeneutic method OR phenomenology OR ethnographic research OR narratives OR discourse
analysis OR qualitative research [Mesh] OR nursing evaluation research [Mesh] OR interview [Publication Type] OR inter-
views as topic [Mesh] OR nursing methodology research [Mesh] OR observation [Mesh] OR grounded theory [Mesh] OR
hermeneutics [Mesh] OR focus groups/methods [Mesh] OR interview*
and
Evaluation Search patient acceptance OR patient perception OR patient perspective OR patient satisfaction OR patient experience OR
patient preference [Mesh] OR patient acceptance of health care [Mesh] OR life change events [Mesh] OR motivation
[Mesh] OR patient motivation OR trust [Mesh] OR patient confidence OR health literacy* OR health knowledge, attitude,
practice OR quality of life OR patient acceptance
and
Research type Search qualitative research [Mesh]
Embase
Sample Search kidney disease* OR kidney failure OR chronic kidney failure OR renal disease* OR renal insufficiency OR chronic
renal insufficiency OR renal replacement therapy OR haemodialysis [Mesh] OR peritoneal dialysis [Mesh] OR dialysis
patient* OR haemodialysis patient [Mesh] OR kidney disease/drug therapy [Mesh] OR chronic kidney failure/drug therapy
[Mesh] OR kidney failure/drug therapy [Mesh] OR renal replacement therapy [Mesh]
and
Phenomenon
of interest
Search medication compliance [Mesh] OR patient compliance [Mesh] OR drug therapy [Mesh] OR treatment refusal [Mesh]
OR drug refusal OR medication refusal OR health knowledge and behaviour OR self-medication [Mesh] OR drug self-
administration [Mesh] OR medication adherence OR patient medication knowledge OR sttitude to health [Mesh] OR poly-
pharmacy OR chronic drug therapy OR drug, prescription OR prescription [Mesh] OR drug efficacy [Mesh]
and
Design Search qualitative research [Mesh] OR qualitative research OR qualitative method OR interview [Mesh] OR qualitative anal-
ysis [Mesh] OR research, nursing [Mesh] OR ethnographic research [Mesh] OR ethnography [Mesh] OR observational
method [Mesh] OR observation [Mesh] OR focus group interview OR clinical nursing research [Mesh] OR grounded theory
[Mesh] OR thematic analysis [Mesh] OR narrative [Mesh] OR phenomenology OR hermeneutics [Mesh] OR phenomenolog-
ical research [Mesh]
and
Evaluation Search patient preference [Mesh] OR patient attitude [Mesh] OR patient satisfaction [Mesh] OR patient experience OR
patient perception OR patient motivation OR motivation [Mesh] OR patient perspective OR Personal experience [Mesh]
OR patient acceptance
and
Research type Search qualitative research [Mesh]
CINAHL
Sample Search kidney disease [Mesh] OR kidney failure, chronic [Mesh] OR renal insufficiency [Mesh] OR renal insufficiency,
chronic [Mesh] OR renal replacement therapy [Mesh] OR haemodialysis [Mesh] OR peritoneal dialysis [Mesh] OR dialysis
patient [Mesh]
and
Phenomenon
of interest
Search patient compliance/drug effects [Mesh] OR treatment refusal/drug effects [Mesh] OR treatment refusal OR pharma-
cological and biological treatments [Mesh] OR health behavior/drug effects [Mesh] OR self-medication [Mesh] OR self-
administration [Mesh] OR patient medication knowledge [Mesh] OR knowledge medication [Mesh] OR medication history
[Mesh] OR drug therapy [Mesh] OR drug therapy OR attitude to health/drug effects [Mesh] OR polypharmacy [Mesh] OR
chronic drug therapy [Mesh] OR drug, prescription [Mesh] OR drugs [Mesh] OR medication adherence OR drug adherence
and
Design Search qualitative research [mesh] OR field study [mesh] or research, nursing [mesh] or ethnographic research [Mesh] or
clinical nursing research [Mesh] OR interview [mesh] OR semi structured interview [Mesh] OR observational method
[mesh] OR participant observation [Mesh] OR non participant observation [Mesh] OR focus group [mesh] or hermeneutics
OR grounded theory [Mesh] OR discourse analysis or thematic analysis or narratives or phenomenological research
[Mesh]
and
(continued)
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participated in the included studies. Of these, 171 patients were
on haemodialysis and/or peritoneal dialysis and 133 patients
attended renal clinics; for 77 patients, treatments were not
clearly described. For a full overview of study characteristics see
Table 3. The studies originated from nine countries (Australia,
Brazil, Canada, Chile, China, Singapore, Sweden, UK and USA).
Data were collected using face-to-face interviews (13 studies),
motivational interviewing via telephone (2 studies), focus group
interviews (2 studies) and face-to-face interviews and observa-
tion/focus group interviews in combination (2 studies). Sample
sizes ranged from 7 to 39 patients and the overall age range was
19–90 years. The majority of studies were assessed to have
minor to moderate methodological limitations (8 low, 6
medium, 5 high).
Table 1. Continued
Search Query
Evaluation Search patient preference OR patient experience OR patient perception or patient attitude [Mesh] OR patient motivation
[Mesh] OR life experience [Mesh] OR patient acceptance or patient perspective OR patient satisfaction OR beliefs or health
belief/drug effects [Mesh] or motivation/drug effects [Mesh] OR motivation or patient participation [Mesh] OR patient par-
ticipation or health literacy
and
Research type Search qualitative research [Mesh]
Fig. 1. Flow diagram illustrating literature search and selection.
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Table 2. Summary of qualitative findings and CERQual assessments
Review finding
Relevant
articles
CERQual
assessment
of confidence
in the
evidence Explanation of CERQual assessment
Logistics
Establishing and maintaining routines [16, 17, 18, 19,
21, 23, 24,
25, 26, 27,
28, 29, 30]
High
confidence
In all, 13 studies with minor to significant
methodological limitations, where
most studies had minor to moderate
methodological limitations (6 low, 4
medium, 3 high). Thick data from six
countries across five geographical con-
tinents, but predominantly high
income countries. High coherence
Establishing and maintaining daily routines in relation to med-
ications facilitated medicine taking. Across studies, patients
described the difficulty of remembering to take their medica-
tions, cope with the complexity of a high pill burden with dif-
ferent dosage times throughout the day and additional
instructions about how and when to take certain medica-
tions. They were also challenged by the task of remembering
to order and renew prescriptions on time, specifically when
medicines ran out at different times. Establishing routines
promoted maintenance of prescriptions and medicine tak-
ing. Changes in established daily routines disrupted medi-
cine taking
The costs of buying medication [16, 25, 27, 28,
29]
Moderate
confidence
In all, five studies with minor to moderate
methodological limitations (three low,
two medium). Moderate data from two
countries (Singapore and Australia)
across two geographical continents and
only high-income countries. High
coherence
The costs associated with buying prescribed medications
reduced medicine taking. Patients who were financially bur-
dened described that they tried to make their supply of med-
ications last longer by skipping some doses, taking lower
doses of medicine than prescribed or, alternatively, asking
their physician to prescribe double-strength medication to
reduce the costs associated with buying medications
Benchmarking the need for medication
Absence of effect from a lay perspective [14, 16, 17, 18,
19, 20, 21,
23, 24, 25,
26, 27, 28,
29, 30]
High
confidence
In all, 15 studies with minor to significant
methodological limitations, where
most studies had minor to moderate
methodological limitations (7 low, 5
medium, 3 high). Thick data from eight
countries across seven geographical
continents and predominantly high-
income countries. High coherence
Absence of any tangible effect of a medication influenced some
patients’ adherence to medication. A majority of patients
prioritized the medications that they believed to be impor-
tant and those they felt produced noticeable effects, that is,
symptom relief, pain relief or improved clinical parameters.
Medications benchmarked as ‘less important’ was most pro-
nounced in patients with few or no symptoms and/or when
patients experienced that ‘less important’ medications were
hard to swallow or tasted bad. Patients also described reduc-
ing dose, timing regime or not taking the medication at all, if
the medication imposed side effects and concerns regarding
potential interactions
Lacking understanding of medication indications and effects [12, 21, 22, 23,
24, 25, 27,
28, 29, 30]
Moderate
confidence
In all, 10 studies with minor to significant
methodological limitations, where
most studies had minor to moderate
methodological limitations (5 low, 3
medium, 2 high). Moderate data from
five countries across four geographical
continents and predominantly high-
income. High coherence
Lacking understanding of the indication for medications, pri-
marily the importance of preventive medications, was a bar-
rier to adherence. Some patients did not know why
medications were prescribed or how they worked, resulting
in a lack of understanding of the importance of taking the
medication. Conversely, knowing why medications were
prescribed and how they worked facilitated adherence
Spurred by emergent symptoms [13, 18, 25, 26,
27]
Moderate
confidence
In all, five studies with minor to signifi-
cant methodological limitations (one
low, two medium, two high). Moderate
data from three countries (UK, USA and
Australia) across three geographical
continents and only high-income coun-
tries. High coherence
Emergent symptoms of disease progression made some
patients regret failing to be adherent to their prescribed
medications despite any side effects. Facing dialysis and dis-
ease-associated complications, these patients reflected on
the importance of medical adherence. Emergent symptoms
changed their benchmarking of the importance of medica-
tions, leading to a higher degree of adherence.
The quality of the patient–physician relationship
Eliciting patients’ wishes for involvement in decisions concern-
ing medication
[12, 13, 14, 15,
18, 22, 23,
24, 25, 26,
27, 28, 29]
High
confidence
In all, 13 studies with minor to significant
methodological limitations, where
most studies had minor to moderate
methodological limitations (5 low, 5
medium, 3 high). Thick data from five
countries across five geographical con-
tinents and predominantly high-
income. High coherence
Eliciting patients’ wishes for involvement in decisions concern-
ing medication influenced some patients’ adherence to med-
ication. Across studies patients expressed different wishes
for being involved in decisions concerning medications.
Some patients placed all their trust in the physicians and
readily left them to take control and make decisions on their
(continued)
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Synthesis
We identified three analytical themes with seven descriptive
subthemes.
(1) ‘Logistics’, with the subthemes establishing and main-
taining routines, and the costs of buying medication.
(2) ‘Benchmarking the need for medication’, with the
subthemes absence of effect from a lay perspective, lacking
understanding of medication indications and effects and being
spurred by emergent symptoms.
(3) ‘Quality of the patient–physician relationship’, with the
subthemes eliciting patients’ wishes for involvement in deci-
sions concerning medication and lacking information.
A summary of the main analytical and descriptive themes
are presented in Table 4. Table 5 presents a selection of patient
quotations illustrating each descriptive theme.
Logistics
The logistics surrounding medicine taking were important for
facilitating or hindering adherence. Logistics involved the prac-
tical challenges of managing complex medication regimes,
numerous prescriptions and health care appointments, all of
which were challenging in the patients’ everyday lives.
Furthermore, logistics included the costs of buying medication.
Establishing and maintaining routines (high CERQual confidence)
Establishing and maintaining daily routines in relation to medi-
cations facilitated adherence. Across studies, patients described
the difficulty of remembering to take medications and coping
with the complexity of a high pill burden, different dosage times
throughout the day and specific instructions about how to take
certain medications. They were also challenged by the task of
remembering to renew prescriptions on time, as prescriptions
expired at different times. Daily routines promoted the mainte-
nance of prescriptions and medicine taking. Facilitating rou-
tines included memory aids (tally charts, calendars, mobile
phone), assisting devices (dosette boxes), taking medicines in
relation to daily activities (meal times or prayers) and reminders
and/or practical support from family or pharmacists (preparing
medications, refilling dosette boxes, ordering and renewing pre-
scriptions, reminders to take medications). Memory aids and
dosette boxes appeared especially important for patients suffer-
ing from fatigue, nausea and poor memory. A downside of dos-
ette boxes was that patients had to be able to see well enough to
read the date and to be able pick up or replace a lost pill with an
identical one [16, 18, 25].
Participating in activities such as family and social gather-
ings, health care appointments and other meetings tended to
disrupt daily routines. Potentially this resulted in patients forget-
ting to take their medication or deliberately leaving it at home
and postponing the medication until later. Frequent changes in
the number of medications, type, dosage and timing of medica-
tions also disrupted established routines and reduced adherence.
The costs of buying medication (moderate CERQual confidence)
In some studies, patients described the costs of buying pre-
scribed medications as a barrier to adherence. Patients who
were financially burdened tried to make their supply of medica-
tions last longer by skipping doses, taking lower doses of medi-
cine than prescribed or, alternatively, asking their physician to
prescribe double-strength medication to reduce the costs of
buying medications.
Benchmarking the need for medication
Benchmarking the need for medication was both a facilitator
and barrier to adherence. Patients used their lay beliefs and
experiences of effects and side effects of medications to bench-
mark which medications were important to take and which
medications could be omitted, completely or occasionally.
Absence of effect from a lay perspective (high CERQual confidence)
Patients prioritized the medications they felt produced notice-
able effects such as symptom relief, pain relief or improved clin-
ical parameters. Effective medications from the perspective of
patients included antihypertensive medications, diabetes medi-
cations and analgesics. Medications with less noticeable effects
were less important to patients and were more likely to be
Table 2. Continued
Review finding
Relevant
articles
CERQual
assessment
of confidence
in the
evidence Explanation of CERQual assessment
behalf while others wished to collaborate as equal partners
with physicians about treatment-related decisions, including
medication. Lack of continuity, time, trust and involvement
of patients wishing to partake in treatment led to patients
taking matters into their own hands in relation to medicine
taking.
Lacking information [14, 18, 22, 23,
24, 25, 28]
Moderate
confidence
In all, seven studies with minor to signifi-
cant methodological limitations, where
most studies had minor to moderate
methodological limitations (three low,
three medium, one high). Moderate
data from four countries across four
geographical continents and only high-
income countries. High coherence
Feeling insufficiently informed about the indications, effects
and side effects and interactions between prescribed medi-
cations affected adherence negatively. Some patients sus-
pected physicians of withholding information while others
described getting conflicting information. For example, dif-
ferent information from different physicians or physician
information that differed from the drug information sheet.
This resulted in confusion and apprehension about the med-
ication, which in some patients posed a barrier to adherence
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skipped. Skipping ‘less important’ medications was most pro-
nounced in patients with few or no symptoms and/or when
patients experienced that ‘less important’ medications were
hard to swallow or tasted bad [14, 16, 17, 19, 25, 33]. These medi-
cations included lipid-lowering agents, histamine H2-receptor
antagonists, calcium, phosphate-binding agents, statins,
aspirin, metoclopramide, pantoprazole and vitamins.
Specifically, calcium and phosphate-binding agents were often
missed because of their size, taste and texture [12, 13, 19, 25, 29].
Patients were also prone to non-adherence when they expe-
rienced that side effects outweighed intended therapeutic
effects. Side effects could range from minor and tolerable to
severe, affecting the patient’s quality of life. Side effects
included loss of appetite, nausea, stomach pain, hair loss, body
aches, muscle pain, weight loss, coated mouth, tremors, dizzi-
ness, skin discoloration, low blood sugar, headache, diarrhoea,
constipation, loss of sexual function or ‘feeling terrible’.
Concerns about side effects and long-term adverse effects of
polypharmacy also affected adherence, with patients altering
doses or the timing of medications or skipping medications to
prevent side effects.
Lacking an understanding of medication indications and effects (moderate
CERQual confidence)
Lacking an understanding of the indication for medications, pri-
marily the importance of preventive medications, was a barrier
to adherence. Some patients did not know why medications
were prescribed or how they worked, resulting in a lack of
understanding of the importance of taking the medication.
Conversely, knowing why medications were prescribed and
how they worked facilitated adherence.
Spurred by emergent symptoms (moderate CERQual confidence)
Patients suffering from disease-related complications expressed
regret about having been non-adherent. Facing dialysis and
disease-associated complications, these patients acknowledged
the importance of medical adherence. Emergent symptoms
changed how they benchmarked the importance of medica-
tions, leading to a higher degree of adherence.
The quality of the patient–physician relationship
The quality of the patient–physician relationship was both a
facilitator and barrier to adherence. Some patients highlighted
that they were more likely to adhere to medications when they
felt well-informed and involved in decisions concerning medi-
cation. Others happily delegated medication decisions. Patients
who lacked information or felt their side effects were not con-
sidered tended to be less adherent to prescribed medications.
Eliciting patients’ wishes for involvement in decisions concerning
medication (high CERQual confidence)
Patients expressed different wishes for being involved in deci-
sions concerning medications. Some placed all their trust in
physicians and readily let the physician take control and make
decisions on their behalf. Others wished to collaborate as equal
partners with physicians about treatment-related decisions,
including medication. They wanted physicians to acknowledge
their concerns and opinions about medication and wished to
discuss the pros and cons of changes in medications, doses and
effects versus side effects. They also wished to discuss how to
manage the disease, the prescribed medication and side effects
to suit their lifestyle preferences, including what to expect if
they chose not to follow the prescribed treatment. Some wished
to negotiate medicine doses in order to minimize side effects. In
several studies, patients experienced insufficient time for dis-
cussing medications with physicians in the outpatient clinic
[16, 18, 19, 33], a large turnover in physicians [16, 17], mistrust of
the reasons for prescriptions (some suspected that medications
were prescribed for research or financial gain) [15, 19, 25, 27]
and non-empathetic communication [14, 15, 17, 19]. Lack of con-
tinuity, time, trust and involvement of patients wishing to par-
take in treatment decisions led to patients taking matters into
their own hands in relation to medicine taking.
Lacking information (moderate CERQual confidence)
Feeling insufficiently informed about the indications, effects,
side effects and interactions of prescribed medications affected
adherence negatively. Some patients suspected physicians of
withholding information, while others described getting con-
flicting information. For example, different information from
different physicians or physician information differed from the
drug information sheet. This resulted in apprehension, which
in some patients posed a barrier to adherence.
Discussion
The aim of this review was to synthesize the available qualita-
tive evidence on patient experiences of factors that facilitate
and hinder adherence to medication in patients with CKD. We
identified three main themes: logistics, benchmarking the need
for medication and the quality of the patient–physician
relationship.
Logistics referred to the complexity of managing and adher-
ing to polypharmacy. Patients’ efforts to cope with this com-
plexity included daily medication routines, aids and practical
help from family and others. We assessed the confidence of the
evidence for this theme to be high. Similar to our findings, a
cross-sectional study of medication adherence among kidney
transplant recipients’ showed that practical barriers, including
Table 4. Summary of the main analytical and descriptive themes
Logistics Benchmarking the need for medication
Quality of the patient–physician
relationship
• Establishing and maintaining routines
(high CERQual confidence)
• Cost of buying medication (moderate
CERQual confidence
• Absence of effect from a lay perspective
(high CERQual confidence)
• Lacking understanding about medica-
tion indication and effects (moderate
CERQual confidence)
• Spurred by emergent symptoms (mod-
erate CERQual confidence)
• Eliciting patients wishes for involvment
in decisions concerning medication
(high CERQual confidence)
• Lacking information (moderate
CERQual confidence)
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Table 5. Selection of quotes from patients to illustrate each descriptive theme
Themes Quotations
Contributing
studies
Logistics
Establishing and
maintaining
routines
‘When you get into a habit, you’re less likely to forget taking one.’ [26] [16, 17, 18, 19, 21,
23, 24, 25, 26,
27, 28, 29, 30]
‘. . .once or twice you might forget or if I am somewhere and the medication is at home or you are
with friends at a particular time you were supposed to have taken the medication when you
don’t have the medication with you so at that time. . .I try not to do that but. . .’ [19]
‘I have, as I said, a table system when my tablets are running out to re-order because there are so
many of them it’s not just as easy as saying once a month, but they all run out different times
and take different levels and what have you. So, I have to keep track of what we’ve got and
when we have got it.’ [24]
‘They’ve [the pharmacy] run out of the drug, go to get the prescription and find the prescription
has run out, got to go back to the doctor to get another prescription before I get another tablet
and that might take a couple of days and then you find you’re back to square one [disease is
uncontrolled].’ [25]
‘. . .I have two pill organizers that I prepare at the same time. . .put five in the first compartment in
the box and the rest in the others. I take the first ones straight away in the morning when I wake
up. . .drink coffee and eat in the morning. . .and then I take my other morning medications.’ [21]
‘. . .my medicine is part of my prayers, okay? So that’s a good way to remember it. Like, I gotta say
my prayers; I have to take my [medication].’ [23]
‘I’m okay if I’m in the house. It’s when I go out. . .half the time I’m sitting thinking I forgot my tab-
lets.’ [18]
‘Has so many pills I get daughter to refill [medicine prescriptions).’ [28]
‘My wife makes sure I take them. . .she helps. She gets all medicines ready.’ [29]
‘Been given new tabs (hypoglycaemic agents) to replace other ones. Does not know what they are-
chemist fills Dosette box.’ [28]
The cost of buy-
ing medication
‘. . .and they cost money more every month. . .I take but I take half. . .sometimes. . .I make test take
half and if I feel OK then OK. . .Lasts longer and save money. . .If I feel bad then I go polyclinic and
take all.’ [16]
[16, 25, 27, 28, 29]
‘I’m living on my savings. . .and a bit of pension and a bit of superannuation. . .so now you only get
one month’s supply, so that makes it much more expensive. . .which is a lot of money when
you’re just living on the pension. It’s just money I saved when I was working.’ [25]
Benchmarking the need for medication
Absence of effect
from a lay
perspective
‘It’s to control the blood pressure for your kidneys. Even if I was to miss the other seven, I will take
that one because I know to keep my blood pressure at a good level.’ [18]
[14, 16, 17, 18, 19,
20, 21, 23, 24,
25, 26, 27, 28,
29, 30]
‘And I said, yeah, well, no problem I’m gonna take [niacin]. It’s a benefit for my heart. . .I’m gonna
go for it. And I took it for a while. . .but I didn’t notice any benefit. I mean, nothing direct. I didn’t
feel it. If I take niacin, or I don’t take it, no difference. I don’t take metoprolol, I know there’s a
difference. I feel different, I feel some fatigue, I feel something missing.’ [23]
‘If my Levomepromazine wasn’t as good and effective for me I wouldn’t take it because of the side
effects.’ [18]
‘I spent a good I’d say at least 6 months dancing around with my treatment, just not taking it seri-
ous. I wouldn’t say really serious, just it seemed a bit excessive the amount of medication. . ..
There’s no way it could be that bad, you feel good, that’s the worst thing about it in the begin-
ning you don’t realize. . .’ [14]
‘Take all the medicines that I need—just not statin and aspirin—and only take half coversyl [peri-
ndopril Prefer ramipril. . .’ [28]
‘I think it’s just calcium tablets; it’s not important. I skip it. I dare not do this with other medicines.’
[20]
‘I had to take [antihypertensive medication], whether it was totally necessary or not, never really
occurred to me, it was more like “well this is a preventative measure,” so if I ran out of prescrip-
tions sometimes I wouldn’t go and get it filled straight away and I’d go for days, sometimes
weeks without taking those medications.’ [25]
‘. . .the tablets are so disgusting, their consistency is so disgusting, so disgusting you don’t want to
take. . . it’s a big enough job taking the pills I’m supposed to take. . .they (the phosphate binding
agent) didn’t taste that great. They’re orange flavoured so that chewing on them is no great joy
. . .the chewable tablet was much too big. You couldn’t take it with you anywhere.’ [21]
‘Sometimes I wonder if it’s the tablets so I miss them to see and it definitely does affect how I feel,
if I’m feeling a bit yucky for a while, feeling a bit nauseous and just want to lie down basically.
So I do get side effects that put me off taking them.’ [24]
‘. . .but then I have other pills against nausea that I add to it. . .my stomach is so weak. . .nourish-
ment first. . .for me it (the phosphate-binding agent) is absorbed just as well after a meal. . .nowa-
days I go and lie down for a while (after taking the phosphate-binding agent). Ten to fifteen
minutes. . .’ [21]
(continued)
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Table 5. Continued
Themes Quotations
Contributing
studies
Lacking under-
standing of
medication
indications
and effects
‘I don’t take medicine for my kidneys; there is no medicine for kidneys, only for high blood pres-
sure. There is one for the heart, which is metoprolol, and there are two for high blood pressure,
which are losartan and amlodipine. I only take these three medicines. And at night I take
simvastatin, but only sometimes; I don’t take it often, because I do the diet and so I sleep well.’
[12]
[12, 21, 22, 23, 24,
25, 27, 28, 29,
30]
‘Well I know what some of them are for but I don’t know what they’re all for. Like when you were
asking me before, merely because I can’t read what’s on the packet, I just pick which ones I like
but I couldn’t tell you which one’s doing what job.’ [25]
‘I’ve managed to get away with it. It’s only the transplant people [who have to take their medi-
cines strictly].’ [27]
Spurred by emer-
gent
symptoms
‘. . .if I had known that not taking my binders would cause my bones to get brittle from the begin-
ning, I would not care how sick they were making me, and. . .keep having side effects and
nobody explained why I have this or what caused it.’ [13]
[13, 18, 25, 26, 27]
‘I was a lot more spasmodic [taking medications] until my kidney function got to a point where it
is now and I’m looking down the barrel of dialysis and that. I’m probably far more regimented
than, and more fearful of not taking it, whereas in the past you know I’ve probably gone six
months without. . .sort of (taking my tablets).’ [25]
‘I wasn’t aware of [the dangers of] blood pressure earlier and if I was, it would have been different.’
[27]
Quality of the patient–physician relationship
Eliciting patients’
wishes for
involvement
in decisions
concerning
medication
‘Explaining the disease to the fullest, the meds, what’s involved, what can happen, changes that
are going to be happening in your life so that when it happens you’re not wondering what’s
going on now.’ [14]
[12, 13, 14, 15, 18,
22, 23, 24, 25,
26, 27, 28, 29]
‘But I. . .I adjust by myself, cause you can’t listen to the doctor all the time, because I don’t know
whether they’re writing a thesis or what, the way they prescribe the medication, every time you
know more and more medications. But it doesn’t work with me. I refuse to listen, I said no, I
don’t want to take. Too much of medication you know. . . ah. Even the renal tablets. . .I never
touch.’ [15]
‘These [two medicines] are for cholesterol, and I was only taking one pill for cholesterol, and my
cholesterol was fine. Sometimes I think these salesmen come around and talk to the doctors
and sell them a bill of goods, and the next thing you know, you’re on it.’ [23]
‘If you read what’s on the prescription [insert] you’d be dead. . .but they should’ve said, “If you
have any side effects such as,” and then only two or three of the major ones. . .Those are not dis-
cussed. So, I had to assume that there’s nothing adverse except in rare cases. Well, it turns out
that’s not true because everyone I’ve mentioned the [edema] to, they didn’t blink an eye. They
sort of smiled, “Oh, we know.” That irritated me a lot. . .They acted as if they were getting paid to
[prescribe it].’ [23]
‘The problem I see is that it’s making me lose my hair. . .They say it aren’t the medicine. But natu-
rally they’re going to say it can’t be the medicine. But what else can it be. . .I’ve tried stopping
them all! I go every other night! Then I notice I don’t lose so much hair. . .He tells me it aren’t got
nothing to do with the medication. But I still believe it does.’ [23]
‘I think I’m the boss in this. . .you’ve got to be the one to do it. So basically I think I’ve played a
major role. The doctor can only guide you; you’ve got to be the one to basically do it.’ [14]
‘Does what doctor tells me to do. I really don’t want to take medicines but doctor tells me I have
to.’ [28]
‘They usually tell me what they’re giving me and why. And what the result should be and that’s
really all I need to know.’ [23]
Lacking
information
‘I think information should be offered in the beginning, it shouldn’t be withheld, and it’s much
harsher to find it out in the end. Hey okay, you’re looking at being on these blood pressure meds
the rest of your life, it’s not going to go away. You need to have that realistic expectation from
the beginning.’ [14]
[14, 18, 22, 23, 24,
25, 28]
‘So see these are things doctors never tell you. . .Everything I get I go home and check it. Every sin-
gle one of my other medicines says the same thing. And you know, you say: “Well, which one is
it?’’’ [23]
‘Now I go to somebody senior to him (previous doctor) and when I go to see him. . .he says. . .well
you shouldn’t have been on this and you shouldn’t have been on that. . .and you do tend to get
confused!’ [22]
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changes in daily routines, were associated with non-adherence
[31]. In another qualitative study, kidney transplant recipients’
reported the importance of developing and maintaining rou-
tines to facilitate medication adherence [22].
Like other studies, we found that memory aids, assisting
devices, associated activities, reminders and practical help from
family and pharmacists facilitated adherence [23, 24, 35]. Living
with a partner or spouse has likewise been shown to increase
adherence [23, 35].
Using tools such as dosette boxes and memory tools may
affect adherence both positively and negatively [1, 23, 36]. These
tools may constitute a potential barrier to adherence for
patients with impaired vision, sensory disturbances or reading
difficulties. Clinicians should also be aware that medicine pack-
aging, memory tools and multicompartment devices such as
dosette boxes do not necessarily increase medication adherence
[1, 36]. They may, however, be helpful for patients who are for-
getful or have practical problems with managing complex medi-
cation regimes [1, 36]. The potential benefits of memory tools
for adherence in patients with physical and/or cognitive impair-
ments warrant further examination.
Adherence improved when patients associated medications
with daily routines. An approach to supporting medication
adherence could be that clinicians systematically help patients
map their everyday activities and encourage them to associate
medication routines with these activities [1, 35–38].
Patients used their lay beliefs and experiences of effects ver-
sus side effects of medications to benchmark which medica-
tions to take and which to potentially omit. The confidence of
the evidence for this theme was high. The Necessity–Concerns
Framework (NCF) suggests that medication adherence is influ-
enced by individual beliefs about the necessity of medications
and their potential adverse effects [39]. For patients in the early
stages of kidney disease who did not experience a high symp-
tom burden, it appeared harder to acknowledge the need for
medications, particularly if unpleasant side effects overshad-
owed therapeutic effects. Studies have previously found that
side effects and the way in which they are addressed by health
professionals influence adherence to medication [23, 24]. Those
patients experiencing side effects that were acknowledged and
well-managed became more adherent [23]. A recent systematic
review found that behavioural interventions for coping with
side effects increased adherence in patients with type 2 diabe-
tes [40]. Acknowledging patient experiences of side effects and
exploring patient preferences for managing side effects, reduc-
ing doses and switching medications are alternative approaches
[1].
The quality of the patient–physician relationship was impor-
tant for adherence. The confidence of the evidence for this
theme was also high. Importantly, while some patients were
happy to delegate medication and other treatment decisions to
physicians, others desired more information, continuity and
involvement in decisions concerning treatment and medica-
tions. These findings are confirmed in a systematic review of
patient preferences for shared decisions in which the majority
of patients preferred shared decisions [41]. Similarly, all studies
identified a subset of patients who wanted to delegate decisions
[41]. Consequently, the challenge for health professionals is to
solicit patient preferences for involvement and tailor consulta-
tions accordingly [41]. Furthermore, health professionals need
to be aware that patient preferences may evolve over time [41].
In line with this, current guidelines urge health professionals to
support patients in making informed decisions about
treatment, including decisions to not take medications if this is
what they wish [1, 36].
Several instruments have been created to elicit patients’
preferences for involvement in decision making, but none
of them have been found feasible in routine clinical settings
[1, 36]. Chewning et al. [41] stress that we need neutral modes of
assessing patient preferences for involvement in decision
making in clinical practice so patients do not feel coerced into
involvement or non-involvement. Measures for assessing
patient wishes should therefore include explicit response
options for both shared decision making and decision delega-
tion [41]. Furthermore, we need insight into how patients per-
ceive decisional processes regarding medications and which
decisions they prefer to share with health professionals [41].
A recent Cochrane review assessing decision aids in people
facing screening and treatment decisions concluded that deci-
sion aids improved people’s knowledge of risks and benefits
and their feeling of being informed and clear about their values
[42]. The authors further concluded that more research is
needed regarding the effect of decision aids on adherence to
decisions taken [42]. There is evidence that educational and
behavioural interventions increase adherence to phosphate
control in adults receiving haemodialysis [43]. Elwyn et al. [44]
expand the field by advocating the potential of integrating
shared decision making and motivational interviewing, an inte-
gration that would be relevant to examine in the context of
medication adherence in patients with CKD.
The strengths of our study include a comprehensive system-
atic review method adhering to the ENTREQ framework, the use
of investigator triangulation to enhance transparency and
reproducibility and the use of the CERQual approach to assess
the confidence in our findings. In our review, we report on
patient-experienced factors influencing adherence to medica-
tion. They correspond to those identified in a World Health
Organization (WHO) report on adherence to medication across a
range of chronic conditions [45]. The focus of our synthesis was
patient-experienced factors. Therefore, we cannot comment on,
for example, political or organizational influences mentioned in
the WHO report [45]. The sample sizes in the included studies
could be characterized as relatively small (median 20).
Nevertheless, all studies reported that data saturation was
achieved. We cannot rule out dissemination bias [46]. In all, 4 of
19 studies included were from the same group of authors. We
cannot rule out that this may have introduced a risk of system-
atic distortion of the phenomenon of interest [11]. We defined
data as all text labelled ‘results’ or ‘findings’, including patient
quotations, as described by Thomas and Harden [9]. This
involved the use of patient quotations gathered in one context
to answer the review question specified in the current article.
To assess the extent to which quotations and other data from
the primary studies supporting our findings were applicable to
the context (perspective or population, phenomenon of interest,
setting) specified in our review question, we used the CERQual
component relevance [11]. We attempted to distinguish varia-
tions in factors influencing adherence across treatments and
stages of disease throughout the analysis. However, it was diffi-
cult to conclude decisively about the influence of, for example,
stages of disease on this basis. Finally, the CERQual approach is
a developing method for assessing how much confidence to
place in findings from a qualitative evidence synthesis [11]. As
it is still under development, experience with the approach is
increasing and will contribute to further development. A limita-
tion of CERQual is that it does not currently address the poten-
tial risk of dissemination bias.
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Implications for research and clinical practice
We need more evidence on the effect of memory tools, includ-
ing digital solutions, in patients with CKD, including those with
cognitive and/or physical impairments. Studies examining the
effect of behavioural interventions for coping with side effects
are also relevant. Furthermore, research into the effect of mod-
els for shared decision making on adherence in patients with
CKD is needed. Finally, additional qualitative studies involving
subgroups of patients with CKD and different treatment regi-
mens and stages of disease are needed to further contextualize
adherence.
Our review suggests that health professionals play an impor-
tant role in influencing patients’ medication adherence. Helping
patients to map daily routines and associate medicine taking
with daily routines may facilitate adherence. Likewise, our find-
ings indicate that health professionals should acknowledge
patients’ wishes for being involved in decisions concerning
medications.
Conclusion
Helping patients to map their everyday activities and associate
medications with everyday activities may facilitate adherence
to medications. Memory aids supported medicine taking in
patients with memory problems. Eliciting patient beliefs and
values about medications and supporting patients to cope with
side effects influenced adherence positively. Finally, a patient-
centred approach addressing patients’ wishes for involvement
in medication decisions facilitated adherence. The findings in
this synthesis resonate with previous research. It extends the
known literature by synthesizing and formally assessing the
confidence in our review findings.
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